Randomized, Double-blind, Placebo-controlled, Multicenter Study Comparing Ciprofloxacin DPI 32.5 mg BID (Twice a Day) Intermittently Administered for 28 Days on / 28 Days Off or 14 Days on / 14 Days Off Versus Placebo to Evaluate the Time to First Pulmonary Exacerbation and Frequency of Exacerbations in Subjects With Non-Cystic Fibrosis Bronchiectasis

Trial Profile

Randomized, Double-blind, Placebo-controlled, Multicenter Study Comparing Ciprofloxacin DPI 32.5 mg BID (Twice a Day) Intermittently Administered for 28 Days on / 28 Days Off or 14 Days on / 14 Days Off Versus Placebo to Evaluate the Time to First Pulmonary Exacerbation and Frequency of Exacerbations in Subjects With Non-Cystic Fibrosis Bronchiectasis

Completed
Phase of Trial: Phase III

Latest Information Update: 23 May 2018

At a glance

  • Drugs Ciprofloxacin (Primary)
  • Indications Bacterial infections; Bronchiectasis
  • Focus Registrational; Therapeutic Use
  • Acronyms RESPIRE-I
  • Sponsors Bayer; Bayer HealthCare
  • Most Recent Events

    • 23 May 2018 Results assessing the impact of Exacerbation Definition in RESPIRE 1 and RESPIRE 2 trials, presented at the 114th International Conference of the American Thoracic Society
    • 01 Jan 2018 Results assessing safety and efficacy published in the European Respiratory Journal
    • 24 May 2017 Results presented at the 113th International Conference of the American Thoracic Society
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top